VLP Therapeutics Receives Notice of Allowance of Key U.S. composition of matter Patent for immune checkpoint PD-1/PD-L1/PD-L2 inserted alphavirus VLP
Patent covers a composition of matter for immune checkpoint PD-1/PD-L1/PD-L2 inserted alphavirus VLP and method of use for cancer therapy Gaithersburg, Md. — April 19, 2017 — VLP Therapeutics, LLC.
Gaithersburg, Md. — February 27, 2017 — VLP Therapeutics, LLC. (“VLP”), a biotechnology company focusing on the research and development of therapeutic and preventative vaccines and antibody agents, today announced
VLP Therapeutics was featured in a TV program in Japan. (January 5, 2017) YouTube https://www.youtube.com/watch?v=X0L8k7Wf7P8
VLP Therapeutics was featured in Asahi Shinbun (November 10, 2016)
VLP Therapeutics was featured in Nikkei Biotech Online (October 11, 2016). https://bio.nikkeibp.co.jp/atcl/news/p1/16/10/09/01662/
VLP Therapeutics Receives Grant from Global Health Innovative Technology (GHIT) Fund to Develop New Vaccine for Dengue Fever
Gaithersburg, Md.-- (PR NEWS WIRE) — October 5, 2016 -- VLP Therapeutics, LLC. announced today that it has received a grant for approximately US$960,000 from the Global Health Innovative Technology